10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

In this article, we examined Mark Lampert’s investment philosophy and decades of experience in the biotechnology space. We also reviewed 10 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. You can skip our detailed discussion and jump directly to 5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund.

Mark Lampert has been investing in small-cap biotechnology companies for decades. He founded the Biotechnology Value Fund/ BVF Inc in 1993, a $4.7 billion investment firm focused primarily on fundamentally driven public biotechnology companies. A Michigan native and an Ann Arbor resident, Lampert served on the boards of directors of a number of private and public companies before founding BVF. His four decades of experience in the biotechnology industry began with a chemistry degree from Harvard College.

As of the end of the June quarter, Mark Lampert’s Biotechnology Value Fund managed $2.6 billion in 13F securities. The fund was composed of 70 stock positions, with top ten holdings concentration of about 54%. Some of the top pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund includes Revolution Medicines, Inc. (NASDAQ:RVMD), Relay Therapeutics, Inc. (NASDAQ:RLAY), Repare Therapeutics Inc. (NASDAQ:RPTX), XOMA Corporation (NASDAQ:XOMA) and Kymera Therapeutics, Inc. (NASDAQ:KYMR).

Besides these top pharma stocks, Mark Lampert’s Biotechnology Value Fund initiated $200 million worth of brand new positions in depression drug-focused GH Research PLC (NASDAQ:GHRS), making it the largest stock holding of the fund’s 13F portfolio. The company’s NASDAQ debut in June garnered a lot of attention from elite funds. Of the 873 elite funds tracked by Insider Monkey, 16 hedge funds were bullish about GH Research PLC  (NASDAQ:GHRS) as of the end of June.

Why pay attention to hedge fund sentiment while choosing stocks?

Insider Monkey’s research was able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by wide margins. Between March 2017 and July 2021, our monthly newsletter’s stock picks returned 186.1%, vs. 100.1% for the S&P 500 ETF (SPY). Our stock picks outperformed the market by more than 86 percentage points (see the details here). That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to. You can subscribe to our free newsletter on our homepage to receive our stories in your inbox.

Let’s start reviewing the top 10 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. We analyzed Biotechnology Value Fund’s 13F filings for this article.

10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

10. Revolution Medicines, Inc. (NASDAQ:RVMD)

 

Biotechnology Value Fund’s Stake Value: $78.8million

 

Percentage of Biotechnology Value Fund’s 13F Portfolio: 2.96% 

 

Number of Hedge Fund Holders: 29

 

Revolution Medicines, Inc. (NASDAQ:RVMD), a developer of therapies to inhibit frontier targets in RAS-addicted cancers, appears like one of the top pharma stocks to buy following the recent selloff. Currently, shares of Revolution Medicines, Inc. (NASDAQ:RVMD) are trading around $27 after hitting a 52-week high of $56 early this year.

The number of long hedge funds positions increased to 29 at the end of the June quarter compared to 26 positions in the previous quarter. Cormorant Asset Management and Farallon Capital, the two leading stakeholders, significantly lifted their positions in Revolution Medicines, Inc. (NASDAQ:RVMD).

9. Relay Therapeutics, Inc. (NASDAQ:RLAY)

 

Biotechnology Value Fund’s Stake Value: $107million

 

Percentage of Biotechnology Value Fund’s 13F Portfolio: 4.03% 

 

Number of Hedge Fund Holders: 17

 

Although hedge fund positions in Relay Therapeutics, Inc. (NASDAQ:RLAY) fell by 3 in the second quarter compared to the prior quarter, leading stakeholders piled into more shares of the company. Oleg Nodelman’s EcoR1 Capital, which is the top hedge fund stakeholder in the company, raised its existing position by 31% to 6.13% of the entire portfolio. 

8. Repare Therapeutics Inc. (NASDAQ:RPTX)

 

Biotechnology Value Fund’s Stake Value: $116 million

 

Percentage of Biotechnology Value Fund’s 13F Portfolio: 4.35% 

 

Number of Hedge Fund Holders: 16

 

Since the second quarter of 2020, Repare Therapeutics Inc. (NASDAQ:RPTX), a precision oncology company, has been a member of Mark Lampert’s Biotechnology Value Fund.

Out of the 873 hedge funds tracked by insider monkey, 16 were bullish on Repare Therapeutics Inc. (NASDAQ:RPTX) in the second quarter compared to 18 positions in the previous quarter.

7. XOMA Corporation (NASDAQ:XOMA)

 

Biotechnology Value Fund’s Stake Value: $120 million

 

Percentage of Biotechnology Value Fund’s 13F Portfolio: 4.50% 

 

Number of Hedge Fund Holders: 4

 

Mark Lampert’s Biotechnology Value Fund has been enjoying a robust share price run of XOMA Corporation (NASDAQ:XOMA) over the years. Since 2017, the stock price of XOMA Corporation (NASDAQ:XOMA) jumped more than 220%, thanks to its growth strategies. The company recently completed a couple of acquisitions including Checkmate Pharmaceuticals’ vidotulimod (CMP-001), One Biopharmaceuticals’ DAY101 (pan-RAF kinase inhibitor), and Denovo Biopharma’s vosaroxin (topoisomerase II inhibitor). 

Despite an aggressive growth strategy, XOMA Corporation (NASDAQ:XOMA) appears in a strong cash position, with a debt-free balance sheet along with a lean expense structure. At the end of the second quarter, XOMA Corporation (NASDAQ:XOMA) had $78.9 million in cash. 

6. Kymera Therapeutics, Inc. (NASDAQ:KYMR)

 

Biotechnology Value Fund’s Stake Value: $127 million

 

Percentage of Biotechnology Value Fund’s 13F Portfolio: 4.78% 

 

Number of Hedge Fund Holders: 21

 

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) are up close to 50% since its debut on NASDAQ in the third quarter of last year. The company’s robust cash position, strong pipeline, and platform expansion plans are adding to investors’ sentiments. As of the end of the second quarter, Kymera Therapeutics, Inc. (NASDAQ:KYMR) had $647 million in cash to support growth activities. 

The number of long hedge funds positions increased to 21 in the second quarter compared to 16 bullish positions in the previous quarter. Biotechnology Value Fund is the leading stakeholder in Kymera Therapeutics, Inc. (NASDAQ:KYMR) with 5.1% of the total ownership in the company, according to the latest filings.

 

Click to continue reading and see 5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund.

 

Suggested articles:

Disclosure: None. 10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund is originally published on Insider Monkey.